MedTrace Logo

LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism

NCT05512715 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-08-23

No results posted yet for this study

Summary

A prospective randomised controlled open label, single centre study. subjects will be randomised into lithium or carbimazole arms in a 1:1 ratio. Lithium arm will receive tab Lithium Carbonate 300mg daily while Carbimazole arm will receive tab Carbimazole 10mg daily for a duration of two months prior to radioactive iodine treatment. Changes in the thyroid hormone levels at 2 months of treatment and at months 1,3 and 6 following radioactive iodine will be evaluated.

Conditions

  • Hyperthyroidism/Thyrotoxicosis

Interventions

PROCEDURE

radioactive iodine

radioactive iodine 15mci

Sponsors & Collaborators

  • Universiti Kebangsaan Malaysia Medical Centre

    lead OTHER

Principal Investigators

  • Norlela Sukor · Hospital Canselor Tuanku Muhriz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-10
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05512715 on ClinicalTrials.gov